Truist lowered the firm’s price target on Zimmer Biomet (ZBH) to $92 from $98 and keeps a Hold rating on the shares. The company delivered 2.9% organic revenue growth in its Q1 earnings beat, but this was shy of buy-side expectations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet: Hold Reiterated as Execution Risks, Salesforce Transition, and CFO Departure Offset Q1 Beat and Margin Upside
- Zimmer Biomet price target lowered to $95 from $100 at JPMorgan
- Zimmer Biomet price target lowered to $105 from $110 at Stifel
- Zimmer Biomet price target lowered to $83 from $93 at Canaccord
- Zimmer Biomet price target lowered to $92 from $100 at Baird